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Lesson
There is a high association of reactive skin presentations,
mainly limited cutaneous vasculitis in patients with cystic
fibrosis and Burkholderia cepcia complex chronic infection.
This may be due to raised levels of circulating inflammatory
mediators.
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The local cystic ﬁbrosis database was used to identify
patients (1992–2012) with Burkholderia cepacia com-
plex and cutaneous involvement using the search
terms ‘vasculitis’, ‘skin’ and ‘other complication’. In
our large adult cystic ﬁbrosis unit of nearly 600
patients, the prevalence of infection with chronic
Burkholderia cepacia complex is 5% (n¼ 30). The
prevalence of cutaneous involvement in patients
with Burkholderia cepacia complex was 23.3%
(n¼ 7). Here, we present the full details of four of
these patients (Table 1).
Case 1
A 26-year-old female with Burkholderia cenocepacia
presented with a two-month history of worsening
ﬁxed purpuric rash on the lower legs (Figure 1).
Skin biopsy conﬁrmed leucocytoclastic vasculitis.
She was treated with dapsone initially without
improvement. On commencement of oral prednisol-
one, there was minimal improvement, which
remained stable. Following this, she was managed
with topical protopic 0.1%.
Case 2
A 23-year-old female with B. cenocepacia developed
an erythematous maculopapular rash on the lower
legs with associated arthropathy of her ﬁnger joints.
This was clinically felt to be reactive leucocytoclastic
vaculitis and a biopsy was not conducted. The vascu-
litis did not respond initially to oral prednisolone, and
she was then commenced on azathioprine and the
rash responded to this. Two years later, she died fol-
lowing a severe infective exacerbation of her chest.
Case 3
A 32-year-old male with a history of B. cenocepacia
and Burkholderia multivorans developed an erythema-
tous rash on the lower legs associated with an infect-
ive exacerbation of his chest. The rash resolved
leaving grey discolouration but would occasionally
ﬂare up in the summer months. The biopsy showed
features of capillaritis, and he was managed with top-
ical steroids and compression hosiery.
Case 4
A 26-year-old female with B. cenocepecia presented
with a history of recurrent small joint pains in asso-
ciation with intermittent painful erythematous nodu-
lar rash on the lower legs. This came on at the onset
of an infective exacerbation of her chest. Biopsy con-
ﬁrmed erythema nodosum. Other causes of erythema
nodosum were excluded, and she did not respond to
Non-steroidal anti-inﬂammatory medications. Her
symptoms continue to relapse in association with
infective exacerbations of her chest.
Of the remaining patients (n¼ 3), one presented
with an erythematous rash on the lower legs and
another had a purpuric rash on the lower legs and
both were diagnosed clinically as leucocytoclastic vas-
culitis by a dermatologist. The third patient presented
with purpuric areas and blistering of the lower legs
which was conﬁrmed as leucocytoclastic vasculitis on
biopsy.
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Overall, two patients had biopsy proven leucocy-
toclastic vasculitis, three were clinically diagnosed
with vasculitis but did not have biopsy conﬁrmation
and two had biopsies, which revealed other patholo-
gies (erythema nodosum and capillaritis), giving an
overall prevalence of cutaneous vasculitis in patients
with Burkholderia cepacia complex of 16.7%. Out of
the ﬁve patients with vasculitis, three had a raised
ESR/CRP ratio.
There was no evidence of renal involvement in any
patient – all had a negative urine dipstick and normal
serum creatinine. The antinuclear antibody and anti-
neutrophil cytoplasmic antibody were negative in all
patients apart from one with biopsy proven leucocy-
toclastic vasculitis who had a transiently positive anti-
neutrophil cytoplasmic antibody. Antistreptolysin O
titre was tested in only two out of the ﬁve patients and
was negative.
Mean forced expiratory volume1 was 30% (range:
18–55) of the predicted value. In four patients (57%),
the forced expiratory volume1 was lower at the time
of presentation with rash compared to the baseline
forced expiratory volume1 values for the previous
two years.
All patients received antibiotics for a presumed
pulmonary exacerbation at onset of the rash. Three
patients received speciﬁc treatment for vasculitis
(prednisolone additional immunosuppressive) after
non-resolution of the rash.
Discussion
Cutaneous vasculitis represents a speciﬁc pattern of
inﬂammation aﬀecting the vessels in the dermis.1 Its
prevalence in the general population is diﬃcult to
estimate as not all cases are biopsied; however, the
estimated incidence of biopsy proven cases is thought
to be between 15 and 60 patients per million
per year.2
Limited cutaneous vasculitis tends to present on
the lower limbs and can be associated with arthral-
gia.3,4 In patients with cystic ﬁbrosis, it has been
described in association with respiratory infections –
including Pseudomonas aeruginosa, Staphylococcus
aureus and Haemophilus inﬂuenza – with several anti-
biotics and also with pancreatic enzyme supple-
ments.4 These associations are thought to result in
antigen excess, which in turn causes a rise in circulat-
ing immune complexes, complement activation and
blood vessel wall damage.1
To our knowledge, vasculitis in association with
Burkholderia cepacia complex has not been reported.
Clinical observations had suggested a proportionately
high frequency of cutaneous vasculitis in this cohort.
We report seven cases of cystic ﬁbrosis patients with
dermatological complications associated with
Burkholderia cepacia complex, of which ﬁve were
cutaneous vasculitis. Importantly, the vasculitis was
limited as there was no evidence of other organ
involvement. These data suggest that the prevalence
associated with Burkholderia cepacia complex is high
(16.7%). Putatively, this may be due to the exuberant
inﬂammatory state associated with Burkholderia cepa-
cia complex, particularly B. cenocepacia. Out of the
30 patients in our cohort with Burkholderia cepacia
complex, 15 (50%) have B. cenocepacia, 13 (43%)
have B. multivorans and two (7%) Burkholderia cepa-
cia. All of our patients in this case series had B. cen-
ocepacia, providing further support for the
association between limited cutaneous vasculitis and
an exuberant inﬂammatory state.
The literature on cutaneous vasculitis in cystic
ﬁbrosis mainly describes the expected typical purpuric
rash on the lower legs; however, maculopapular
rashes have also been described.3 This may reﬂect
an early stage of the vasculitis prior to blood vessel
wall damage and red cell extravasation, characterised
by palpable purpura. Bullae and ulceration may be
present in severe cases.
As mentioned previously, medications including
antibiotics and pancreatic supplements are estimated
to be the cause in up to 15% of cutaneous vasculitis.1
In patients with cystic ﬁbrosis, isolating a causative
drug can be diﬃcult due to polypharmacy and recur-
rent requirement for antibiotics. In our cohort, the
symptoms of vasculitis preceded any new
medications.
Henoch-Schonlein purpura is an important diﬀer-
ential to consider, as it tends to be self-limiting and
treatment is mainly supportive. Antistreptolysin O
Figure 1. Clinical appearance of the legs of patient 1; rash
with haemosiderin related and post inflammatory pigment
change following vasculitis.
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titres can be positive in up to 50% of patients with
cutaneous vasculitis in general. Interestingly, b-hae-
molytic Streptococcus is rarely isolated from the
sputum of patients with cystic ﬁbrosis.1
The associated feature of joint pains in ﬁve of
our patients is interesting, and is also echoed in the
cystic ﬁbrosis literature with various cases of cuta-
neous vasculitis.5,6 An episodic arthropathy is com-
monly described; the underlying mechanism has not
been fully elucidated but it probably shares a
common inﬂammatory pathway with cutaneous
vasculitis, as both are characterised by raised circu-
lating immune complexes, particularly during pul-
monary exacerbations.5 None of our patients had
a persistently positive serum antineutrophil cyto-
plasmic antibody. This is in contrast to patients
with chronic P. aeruginosa infection, where antineu-
trophil cytoplasmic antibody (IgA/IgG) against bac-
tericidal permeability increasing (BPI) protein is
often found.7
Cystic ﬁbrosis patients with Burkholderia cepacia
complex have a varied clinical outcome from asymp-
tomatic carriage to rapid forced expiratory volume1
decline.8 B. cenocepacia is of particular importance,
as it demonstrates increased virulence and worse out-
comes.9 Although some studies have demonstrated an
association between forced expiratory volume1 decline
and vasculitis,3 we were unable to conﬁrm this due to
the limited number of patients in our cohort.
Treating cutaneous vasculitis should be aimed at
treating the underlying cause where possible. Eight
per cent of our cohort did not respond to treatment
of a pulmonary exacerbation and were treated with
oral steroids alone, or in conjunction with azathiopr-
ine or ciclosporin and demonstrated modest results.
There is evidence in the literature for all of the treat-
ments used1,3,4,10; however, immunosuppressive
agents especially in cystic ﬁbrosis must be used with
caution due to the theoretical risk of attenuating host
defence mechanisms to infections. In general, potent
topical steroids in combination with oral steroids,
dapsone or colchicine are considered ﬁrst-line treat-
ments for patients with ongoing cutaneous vasculitis.1
In conclusion, we have presented a case series of
limited cutaneous vasculitis and two cases of other
reactive skin presentations in association with
Burkholderia cepacia complex. Our data suggest a
high prevalence of skin complications, which is prob-
ably due to high levels of circulating inﬂammatory
mediators with chronic Burkholderia cepacia complex
infection. We recommend a systematic approach to
patient evaluation including screening for infectious
triggers, drugs and systemic involvement, and early
lesional skin biopsy for histology and immunoﬂuor-
escence to guide treatment.
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